JOURNAL OF HEALTH SCIENCE AND MEDICAL TECHNOLOGY
2026 Vol. 1, No.1

Medical Nanorobotics: Key Technologies and Clinical Prospects

Duoduo Mou

Faculty of Computing, Universiti Teknologi Malaysia

Corresponding Author*: Duoduo Mou E-mail: mouduoduo@graduate.utm.my

ARTICLE INFO

Keywords

medical nanorobotics; targeted drug delivery; nano-actuation; biocompatible nanomaterials; in vivo navigation; cancer therapy; micromotors; clinical translation

ABSTRACT

Medical nanorobotics represents a rapidly emerging interdisciplinary frontier that integrates nanotechnology, robotics, materials science, and biomedical engineering to enable highly targeted diagnosis and therapy at the cellular and molecular levels. Unlike conventional drug delivery and minimally invasive surgery, nanorobots and nano-scale active systems can potentially navigate within biological environments, sense pathological changes, and perform localized therapeutic interventions with unprecedented precision. Recent advances in micro/nano-fabrication, biocompatible materials, propulsion mechanisms, and real-time imaging have significantly accelerated the feasibility of nanorobotic platforms. Meanwhile, artificial intelligence and bioinspired design approaches are improving autonomous navigation and adaptive control in complex physiological conditions. Despite these technological breakthroughs, clinical translation remains constrained by challenges in safety, immune compatibility, in vivo controllability, scalability of manufacturing, and regulatory uncertainty. This paper systematically reviews the key enabling technologies of medical nanorobotics, including structural design, actuation and propulsion strategies, sensing and communication methods, navigation and control systems, and biointegration. Furthermore, the paper discusses the most promising clinical application domains such as targeted drug delivery, cancer therapy, thrombolysis, antimicrobial treatment, precision surgery, and diagnostics. Finally, it outlines major barriers to clinical deployment and proposes future research directions toward safe, scalable, and clinically validated nanorobotic systems.

Citation:

1. Introduction

Medical nanorobotics refers to the design and deployment of nano- to micro-scale robotic agents capable of performing biomedical tasks inside the human body. These agents are not necessarily “robots” in the traditional mechanical sense, but rather engineered nano-structures or micromachines that can actively respond to stimuli, move in biological fluids, interact with tissues, and deliver therapeutic payloads in a controlled manner. The promise of nanorobotics lies in overcoming limitations of conventional medicine, including systemic drug toxicity, low therapeutic concentration at disease sites, invasive surgical procedures, and poor sensitivity of early-stage diagnostics.

The concept of nanorobots has long been discussed in theoretical biomedical engineering, but only in recent decades has experimental progress enabled functional prototypes. Contemporary nanorobotic systems include magnetically controlled helical swimmers, ultrasound-driven micromotors, chemically powered catalytic nanorockets, and biohybrid microrobots based on sperm cells or bacteria. These systems aim to achieve active locomotion, controlled steering, and site-specific therapeutic action.

At the same time, medicine increasingly demands precision. The rise of personalized therapy, immune-oncology, and regenerative medicine has revealed that many diseases cannot be effectively treated through systemic administration of drugs. For example, chemotherapy remains limited by off-target toxicity, while antibiotics face the accelerating threat of antimicrobial resistance. The need for localized intervention, combined with advanced imaging technologies and nanofabrication, has made nanorobotics an appealing solution.

Recent experimental achievements demonstrate that micro/nano swimmers can travel through viscous fluids, penetrate tissue-like environments, and deliver drugs in model organisms. However, significant gaps remain between laboratory success and clinical translation. Major obstacles include immune clearance, limited in vivo power sources, uncertain long-term toxicity, lack of standardized evaluation metrics, and manufacturing scalability. Addressing these issues requires systematic research into enabling technologies and clinical pathways.

This paper provides a structured review of key technologies underpinning medical nanorobotics, followed by an analysis of major clinical prospects and translational challenges. The objective is to provide an integrated perspective on the technological roadmap and the feasibility of future clinical deployment.

2.Fundamentals of Medical Nanorobotics

2.1 Definition and Classification of Nanorobotic Systems

Medical nanorobots can be broadly defined as engineered nano-scale or micro-scale devices capable of performing controlled actions within biological environments. In practice, many so-called “nanorobots” are actually in the micrometer range, since pure nanometer-scale robots face severe constraints in propulsion efficiency, payload capacity, and precise controllability. Nevertheless, the term nanorobotics is widely used to describe active micro/nano agents designed to operate at cellular and subcellular scales.

From a functional perspective, nanorobotic systems can be classified into several categories, including externally actuated nanorobots controlled through magnetic fields, ultrasound, light, or electric stimulation; chemically powered nanorobots propelled by catalytic reactions using surrounding biological fuels; and biohybrid nanorobots that utilize living cells such as bacteria, sperm, or macrophages for propulsion or guidance. In addition, swarm nanorobots consist of multiple micro/nano agents coordinated to perform collective behaviors, while stimuli-responsive nanocarriers are nano-assemblies that may not exhibit active motility but still demonstrate robot-like responsiveness through environmental sensing.

The key distinction between passive nanocarriers and true nanorobots lies in the presence of controllable actuation or adaptive behavior. Active nanorobots introduce a new paradigm in which movement and therapeutic functions can be externally directed or autonomously triggered, thereby expanding the potential of precision medicine and targeted intervention at the micro-scale.

2.2 Biological Constraints and Design Requirements

Nanorobots must operate in highly complex physiological environments, where blood, mucus, lymph, cerebrospinal fluid, and interstitial spaces impose distinct mechanical and biochemical constraints. At micro- and nano-scales, fluid dynamics are dominated by low Reynolds number physics, meaning inertia becomes negligible and effective propulsion must rely on non-reciprocal motion. This fundamentally changes how locomotion systems must be engineered and increases the difficulty of achieving stable, controllable movement in vivo.

In addition, the biological environment introduces multiple barriers that directly affect nanorobot stability and functionality, including rapid immune clearance by macrophages and complement proteins, protein corona formation that alters surface properties and targeting performance, potential biological toxicity caused by reactive oxygen species generation or membrane disruption, biodistribution limitations due to accumulation in organs such as the liver, spleen, and kidneys, and strict safety requirements demanding biodegradability or reliable retrieval. Therefore, medical nanorobots must be designed with biocompatibility, immune stealth, controlled degradation, and minimal off-target effects as central principles to ensure feasibility for clinical applications.

3.Key Technologies Enabling Medical Nanorobotics

3.1 Structural Design and Nanofabrication

The fabrication of nanorobots depends on advanced micro/nano engineering methods such as lithography, electrodeposition, self-assembly, and 3D nano-printing. Helical swimmers, for example, require precisely structured screw-like geometries that convert rotational motion into forward propulsion under magnetic actuation. These designs are inspired by bacterial flagella and rely on controlled asymmetry.

Recent progress in two-photon polymerization and nanoscale additive manufacturing enables complex architectures with high reproducibility. These fabrication approaches support multifunctional nanorobots integrating propulsion, drug reservoirs, and sensing elements. However, the cost and throughput of these methods remain limiting for mass production. One

notable development is the creation of multifunctional micro/nano motors that incorporate layered materials for propulsion and drug loading. Such architectures allow controlled drug release triggered by environmental stimuli or external signals, demonstrating the importance of structural integration in medical nanorobotics [1].

3.2 Materials and Biocompatibility Engineering

Material choice is central to nanorobot performance. Common materials include gold, titanium, silica, polymers, graphene derivatives, and magnetic nanoparticles. Biodegradable polymers such as PLGA are often favored for clinical translation due to their established regulatory acceptance. Surface functionalization is equally important. Polyethylene glycol (PEG) is widely used to reduce immune recognition, while antibody conjugation can enhance targeting specificity. Recent research emphasizes zwitterionic coatings and biomimetic membranes to reduce protein corona effects. Magnetic nanorobots often incorporate iron oxide nanoparticles due to their favorable magnetic properties and relatively low toxicity. However, accumulation and long-term clearance remain concerns. Studies have shown that surface engineering can significantly reduce immune cell uptake and improve circulation time, which is essential for clinical feasibility [2].

3.3 Propulsion and Actuation Mechanisms

Propulsion is one of the defining technological challenges in medical nanorobotics. Nanorobots require reliable movement in highly viscous biological fluids, where low-Reynolds-number conditions significantly constrain locomotion efficiency. To address these limitations, several propulsion strategies have been developed.

3.3.1 Magnetic Actuation

Magnetic propulsion is widely regarded as one of the most promising actuation strategies for clinical translation because externally applied magnetic fields can penetrate biological tissues without causing direct damage. Magnetic helical swimmers can be driven by rotating magnetic fields, converting rotational torque into forward propulsion through corkscrew-like motion, while steering can be achieved through magnetic gradients or field modulation. Magnetic control has been demonstrated in vivo in small animal models, supporting the feasibility of guiding microrobots through blood vessels and other confined fluidic spaces. Importantly, magnetic actuation does not rely on chemical fuels, which reduces toxicity risks and improves biocompatibility. Owing to their stable locomotion and strong controllability, magnetic helical microrobots are often considered a benchmark platform for future medical nanorobotic applications [3].

3.3.2 Chemical Propulsion

Chemical propulsion uses catalytic reactions to generate thrust, such as hydrogen peroxide decomposition on platinum surfaces. However, many chemical fuels are toxic or incompatible with human physiology. Recent approaches explore biocompatible fuels like glucose, urea, or gastric acid. Despite exciting laboratory results, chemical propulsion remains difficult for clinical translation because controlling reaction rates and avoiding harmful byproducts is challenging. Nevertheless, catalytic nanomotors remain an important research direction for autonomous actuation [4].

3.3.3 Ultrasound and Acoustic Propulsion

Ultrasound-driven propulsion leverages acoustic waves to create microstreaming or bubble oscillation forces. This method offers deep tissue penetration and the possibility of real-time control. Acoustic microrobots can move without onboard chemical fuels and can operate in blood-like environments. Acoustic actuation also provides potential synergy with ultrasound imaging, allowing combined navigation and monitoring. Recent studies demonstrate the feasibility of ultrasound-powered micro-swimmers for drug delivery in confined spaces [5].

3.3.4 Light-Driven and Photothermal Actuation

Light-driven propulsion can be achieved through photochemical reactions or photothermal gradients generated by external irradiation. While optical control offers high precision and flexible spatiotemporal regulation, its tissue penetration depth is inherently limited, especially for visible wavelengths due to scattering and absorption. Near-infrared light can improve penetration and reduce photodamage, but it still faces significant constraints for targeting deep organs and internal lesions. Nevertheless, photothermal nanorobots may be particularly effective for superficial tumors, localized tissue ablation, or endoscopic delivery contexts where illumination can be applied directly. In addition, they can generate localized hyperthermia to enhance tumor destruction or synergize with other anticancer therapies, highlighting their therapeutic potential in precision oncology [6].

3.4 Navigation, Localization, and Control Systems

Navigation in medical nanorobotics requires not only precise motion control but also reliable localization and tracking. While in vitro environments enable direct observation through optical microscopy, in vivo tracking is significantly more challenging due to tissue opacity and complex physiological conditions. Current localization strategies mainly rely on medical imaging modalities such as magnetic resonance imaging (MRI), fluorescence imaging, ultrasound imaging, photoacoustic imaging, and X-ray imaging. Each technique involves trade-offs among spatial resolution, penetration depth, temporal responsiveness, and safety. For instance, MRI provides excellent soft tissue contrast but is costly and often limited in real-time feedback, whereas ultrasound is widely accessible and fast but typically lacks sufficient resolution for nanoscale objects.

In addition to imaging-based localization, control strategies increasingly explore swarm-based approaches, where multiple nanorobots are guided collectively rather than individually, thereby reducing dependence on precise single-agent tracking. This collective control paradigm can improve robustness and enhance the feasibility of clinical deployment, since therapeutic effectiveness may be achieved through coordinated group behavior even when individual robot trajectories cannot be clearly resolved. In particular, swarm control under external magnetic fields has been proposed as a scalable strategy for future medical nanorobotic systems [7].

3.5 Sensing, Communication, and Functional Payload Integration

Nanorobots must sense their environment to perform targeted actions. Sensors may detect pH changes, enzymatic activity, biomarkers, or temperature variations. Many nanorobots integrate stimuli-responsive drug release systems that trigger payload delivery in tumor

microenvironments characterized by acidity or hypoxia. Communication remains a major challenge because traditional wireless methods cannot be miniaturized to the nanoscale. Instead, nanorobots may communicate indirectly through collective behavior, chemical signaling, or externally mediated control.

Integration of functional payloads such as chemotherapy drugs, gene therapy vectors, or antimicrobial agents is essential for therapeutic value. Drug-loading strategies include nanoporous reservoirs, polymer encapsulation, and surface adsorption. Controlled release can be triggered by external stimuli such as heat, ultrasound, or magnetic fields. Advanced multifunctional nanorobots have demonstrated simultaneous imaging and therapy (theranostics), enabling real-time monitoring of treatment effects [8].

4.Biomedical Applications and Clinical Prospects

4.1 Targeted Drug Delivery and Precision Therapy

The most direct application of nanorobotics is targeted drug delivery. Conventional nanoparticles rely on passive accumulation via the enhanced permeability and retention effect, but this is inconsistent across patients. Active nanorobots can potentially overcome this by navigating directly to target tissues. Magnetically guided nanorobots have been used to deliver drugs to localized sites in animal models. This improves drug concentration at the disease site while reducing systemic toxicity. Targeted delivery is particularly relevant for chemotherapy agents with narrow therapeutic windows. Furthermore, nanorobots can be designed to release drugs only when encountering specific microenvironmental cues, such as low pH in tumors. Such responsive systems increase specificity and minimize side effects [9].

4.2 Cancer Therapy and Tumor Microenvironment Intervention

Cancer treatment remains one of the most promising application domains for medical nanorobotics. Tumors typically exhibit distinctive microenvironmental characteristics, including abnormal vasculature, hypoxia, acidic pH, and elevated enzymatic activity, which provide exploitable cues for nanorobot targeting, activation, and controlled drug release. Based on these features, nanorobotic cancer therapies may enable localized chemotherapy delivery, photothermal ablation, tumor vessel occlusion, immune microenvironment modulation, and targeted gene editing delivery, thereby improving treatment precision while reducing systemic toxicity. A particularly innovative strategy involves DNA-based nanorobots engineered to carry thrombin directly to tumor-associated blood vessels, triggering selective coagulation and effectively cutting off the tumor blood supply. This approach demonstrates that nanorobotics can extend beyond conventional drug delivery toward more active and functional biological manipulation within the tumor microenvironment [10].

4.3 Thrombolysis and Cardiovascular Interventions

Thrombosis is a major cause of stroke and myocardial infarction. Although current thrombolytic therapy can be effective, it is limited by systemic bleeding risks and inadequate local drug delivery. Nanorobots offer the possibility of localized clot disruption with improved precision. Magnetic microrobots could be guided to clot sites, mechanically disrupt thrombi, or deliver clot-dissolving enzymes such as tPA in a targeted manner. In addition, micro-drillers

powered by rotating magnetic fields may physically break down clots and accelerate recanalization. Such strategies could reduce systemic drug exposure and improve overall safety. Experimental demonstrations of microrobots performing mechanical thrombolysis support this application pathway [11].

4.4 Antimicrobial Therapy and Biofilm Eradication

Biofilms are a significant clinical challenge in chronic infections and implanted medical devices. Antibiotics often fail because biofilms form protective extracellular matrices that block drug penetration. Nanorobots can potentially penetrate biofilms mechanically and deliver antimicrobial agents directly. Magnetic nano-swarms have been proposed to physically disrupt biofilm structures, increasing drug susceptibility. Additionally, nanorobots can generate localized reactive oxygen species or heat to destroy microbial communities. Such systems are promising for catheter infections, chronic wounds, and dental plaque. Research has shown that active micro/nano systems can enhance biofilm disruption compared to passive nanoparticles [12].

4.5 Minimally Invasive Surgery and Tissue Repair

Nanorobotics may transform surgery by enabling ultra-minimally invasive interventions. Potential applications include micro-scale tissue cutting, localized ablation, and targeted cauterization. For example, magnetically controlled micro-grippers have been developed to capture tissue samples or remove debris. Similarly, micro-drillers can penetrate tissue barriers. In regenerative medicine, nanorobots may deliver growth factors or stem cell signaling molecules to damaged tissues. They may also serve as scaffolding components for tissue repair. Such approaches could improve wound healing and organ regeneration outcomes [13].

4.6 Diagnostics, Imaging, and Biosensing

Nanorobots can serve as active diagnostic agents. Instead of waiting for biomarkers to diffuse into blood, nanorobots could travel to tissues, sense pathological markers, and transmit signals through imaging modalities. For example, nanorobots can be engineered with contrast-enhancing components for MRI or ultrasound imaging. They can also detect enzymatic activity or tumor acidity, acting as mobile biosensors. Active diagnostic nanorobots may allow earlier detection of cancers or inflammatory diseases. Integration of imaging contrast materials with motile nanostructures has been explored as a pathway for next-generation diagnostic tools [14].

5.Challenges in Clinical Translation

5.1 Safety, Toxicity, and Long-Term Biodegradation

The most critical requirement for clinical translation is safety. Nanorobots must avoid causing inflammation, toxicity, or organ accumulation. Even materials considered biocompatible at macro-scales may behave differently at nano-scales due to surface reactivity. Long-term biodegradation is also essential. Non-degradable nanorobots may accumulate in liver or spleen, posing unknown risks. Biodegradable materials such as magnesium, calcium-based composites, and polymeric structures are therefore being explored.

Additionally, nanorobots must avoid inducing clot formation, hemolysis, or endothelial damage. Systematic toxicological studies are needed, and regulatory agencies will require long-term evidence before approving clinical use. Concerns about nanoparticle accumulation have already been raised in nanomedicine, indicating the strict safety expectations nanorobotics will face [15].

5.2 Immune System Interactions and Biological Barriers

Nanorobots must evade immune clearance long enough to reach target tissues. Macrophages and neutrophils can rapidly engulf foreign particles. Protein corona formation can mask targeting ligands and change biodistribution. To address these issues, researchers have explored biomimetic cloaking using red blood cell membranes, platelet membranes, and leukocyte membranes. Such strategies can reduce immune recognition and improve circulation time. However, immune evasion may introduce new risks, such as unexpected immune modulation. Understanding immune-nanorobot interactions is therefore essential. Recent research emphasizes that immunological compatibility is not only about avoidance but also about controlled and predictable immune engagement [16].

5.3 Real-Time Tracking and Control in Deep Tissue

Tracking nanorobots inside the human body remains a major challenge for clinical translation. Most existing demonstrations rely on transparent models or small animals, while in humans deep-tissue monitoring depends on MRI, ultrasound, or X-ray imaging, which often cannot resolve single nanorobots with sufficient sensitivity. This creates a dilemma: clinical systems may require swarms large enough to be detectable, but swarm deployment increases control complexity and safety risks such as aggregation and off-target accumulation. Therefore, improving imaging sensitivity and integrating imaging with closed-loop control will be essential, and magnetic particle imaging may provide a promising solution for tracking magnetic nanorobots with higher accuracy [17].

5.4 Power Supply, Autonomy, and Reliability

Unlike traditional robots, nanorobots cannot carry batteries. They must rely on external fields or chemical energy sources. External control offers reliability but requires complex equipment and limits deployment contexts. Autonomous chemical propulsion is attractive but difficult to regulate in vivo. The ideal solution may involve hybrid systems combining external steering with local autonomous behaviors. Reliability is also essential: nanorobots must perform consistently under variable physiological conditions. Differences in blood viscosity, flow velocity, and immune response across patients could dramatically affect performance. Ensuring robust behavior under uncertainty is a major engineering problem [18].

5.5 Manufacturing Scalability and Standardization

Clinical deployment requires scalable manufacturing. Many current fabrication techniques are slow, expensive, and unsuitable for mass production. Additionally, batch-to-batch variation in nano-scale devices can be substantial. Standardization of performance metrics is also lacking. For example, there is no universal benchmark for propulsion efficiency, targeting accuracy, or biodegradation timelines. Regulatory bodies will demand reproducible production and validated testing standards.

Scaling nanorobot manufacturing to clinical-grade quality is therefore not just a technical challenge but also an industrial and regulatory barrier. Recent studies emphasize the importance of translating laboratory prototypes into standardized, GMP-compliant production pipelines [19].

5.6 Ethical and Regulatory Considerations

Nanorobotics introduces unique ethical concerns. Active agents operating inside the body raise questions about patient consent, controllability, unintended tissue interactions, and post-treatment clearance. Regulatory classification is also unclear. Nanorobots may be categorized as medical devices, drug delivery systems, biologics, or combination products. Each pathway involves different approval requirements.

Moreover, the possibility of remotely controlled agents may raise concerns about cybersecurity and misuse. While such risks are speculative, regulatory frameworks must anticipate them. Governance models for nanorobotic medicine will need to evolve in parallel with technological development [20].

6.Future Directions of Medical Nanorobotics

6.1 Bioinspired and Biohybrid Nanorobotic Platforms

Future nanorobots may increasingly rely on biological components. Biohybrid robots using bacteria or sperm cells as propulsion units demonstrate that living organisms already provide efficient locomotion in biological fluids. Integrating synthetic control mechanisms with biological propulsion could enable higher efficiency and adaptability. Bioinspired designs may also improve navigation in confined environments. For example, mimicking immune cell migration could allow nanorobots to move through tissues rather than only fluids.

6.2 AI-Enabled Swarm Control and Adaptive Navigation

Artificial intelligence may enable adaptive control strategies for nanorobot swarms. Instead of direct manual steering, AI could interpret imaging feedback and adjust field parameters dynamically. Swarm robotics principles can also improve robustness. Even if individual agents fail, collective behavior can still achieve therapeutic effects. This redundancy is particularly attractive for clinical translation.

6.3 Biodegradable and Self-Destructing Nanorobots

A key trend is the development of biodegradable nanorobots that safely dissolve after completing their tasks. Materials such as magnesium alloys, biodegradable polymers, and calcium phosphate composites may enable this. Self-destructing mechanisms could also be externally triggered to ensure safety. Such designs would reduce long-term toxicity and simplify regulatory approval.

6.4 Integration with Personalized and Precision Medicine

Nanorobotics will likely become part of precision medicine. Personalized targeting ligands, patient-specific imaging guidance, and individualized drug payloads may allow tailored treatment. For example, nanorobots could be designed to respond to biomarkers unique to a patient’s tumor.

This would increase therapeutic effectiveness and reduce off-target toxicity.

7. Conclusion

Medical nanorobotics represents a transformative paradigm in biomedical technology, offering the potential for highly precise diagnosis and therapy within the human body. Advances in nanofabrication, biocompatible materials, propulsion mechanisms, and imaging-guided navigation have enabled functional prototypes capable of targeted delivery, tumor therapy, thrombolysis, antimicrobial intervention, and diagnostic sensing. Among propulsion approaches, magnetic and acoustic actuation appear most promising for clinical translation due to their controllability and biocompatibility.

Nevertheless, the path toward real-world clinical deployment remains challenging. Key limitations include toxicity risks, immune clearance, lack of reliable deep-tissue tracking, insufficient manufacturing scalability, and regulatory uncertainty. Future progress will require multidisciplinary integration of nanotechnology, robotics, imaging science, AI-based control, and clinical validation.

If these challenges can be addressed, nanorobotics may evolve from laboratory prototypes into practical clinical tools, enabling next-generation precision medicine and reshaping how complex diseases are diagnosed and treated.

References

[1] W. Gao, X. Feng, A. Pei, C. R. Kane, R. Tam, C. Hennessy, and J. Wang, “Bioinspired helical microswimmers based on vascular endothelium,” ACS Nano, vol. 8, no. 4, pp. 3170–3180, 2014.

[2] S. Martel, “Magnetic micro- and nanorobots for medical applications,” Annual Review of Biomedical Engineering, vol. 17, no. 1, pp. 1–25, 2015.

[3] L. Zhang, J. J. Abbott, L. Dong, B. E. Kratochvil, D. Bell, and B. J. Nelson, “Artificial bacterial flagella: Fabrication and magnetic control,” Applied Physics Letters, vol. 94, no. 6, pp. 064107-1–064107-3, 2009.

[4] J. Wang and W. Gao, “Nano/microscale motors: Biomedical opportunities and challenges,” ACS Nano, vol. 6, no. 7, pp. 5745–5751, 2012.

[5] T. Xu, W. Gao, L. P. Xu, X. Zhang, and S. Wang, “Fuel-free synthetic micro/nanomachines,” Advanced Materials, vol. 29, no. 9, pp. 1603250-1–1603250-18, 2017.

[6] S. Sánchez, L. Soler, and J. Katuri, “Chemically powered micro- and nanomotors,” Angewandte Chemie International Edition, vol. 54, no. 5, pp. 1414–1444, 2015.

[7] A. Ceylan, K. Sitti, and M. Sitti, “Magnetic soft microrobots for bioinspired locomotion,” Advanced Materials, vol. 29, no. 30, pp. 1605072-1–1605072-11, 2017.

[8] B. Esteban-Fernández de Ávila, P. Angsantikul, J. Li, W. Gao, L. Zhang, and J. Wang, “Micromotors go in vivo: From test tubes to live animals,” Advanced Functional Materials, vol. 28, no. 25, pp. 1705640-1–1705640-17, 2018.

[9] M. Xuan, Z. Wu, J. Shao, L. Dai, T. Si, and Q. He, “Near infrared light-powered Janus mesoporous silica nanoparticle motors,” Journal of the American Chemical Society, vol. 138, no. 20, pp. 6492–6497, 2016.

[10] L. Li, S. Liu, H. Li, H. Wang, and Y. Liu, “DNA nanorobot for targeted cancer therapy through tumor vessel occlusion,” Nature Biotechnology, vol. 36, no. 3, pp. 258–264, 2018.

[11] J. Yu, D. Jin, K. Chan, Q. Wang, and L. Zhang, “Magnetically driven microdrillers for mechanical thrombolysis,” Advanced Functional Materials, vol. 29, no. 5, pp. 1807855-1–1807855-10, 2019.

[12] X. Chen, M. Hoop, F. Mushtaq, E. Siringil, C. Hu, B. J. Nelson, and S. Pané, “Recent developments in magnetically driven micro- and nanorobots,” Applied Materials Today, vol. 9, no. 1, pp. 37–48, 2017.

[13] D. Gracias, “Stimuli responsive self-folding using thin polymer films,” Current Opinion in Chemical Engineering, vol. 2, no. 1, pp. 112–119, 2013.

[14] A. Servant, F. Qiu, M. Mazza, K. Kostarelos, and B. J. Nelson, “Controlled in vivo swimming of a swarm of bacteria-like microrobotic flagella,” Advanced Materials, vol. 27, no. 19, pp. 2981–2988, 2015.

[15] A. Nel, T. Xia, L. Mädler, and N. Li, “Toxic potential of materials at the nanolevel,” Science, vol. 311, no. 5761, pp. 622–627, 2006.

[16] S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak, and W. C. W. Chan, “Analysis of nanoparticle delivery to tumors,” Nature Reviews Materials, vol. 1, no. 5, pp. 16014-1–16014-12, 2016.

[17] K. M. Krishnan, “Biomedical nanomagnetics: A spin through possibilities in imaging, diagnostics, and therapy,” IEEE Transactions on Magnetics, vol. 46, no. 7, pp. 2523–2558, 2010.

[18] M. Sitti, “Miniature devices: Voyage of the microrobots,” Nature, vol. 458, no. 7242, pp. 1121–1122, 2009.

[19] P. D. Howes, R. Chandrawati, and M. M. Stevens, “Colloidal nanoparticles as advanced biological sensors,” Science, vol. 346, no. 6205, pp. 1247390-1–1247390-10, 2014.

[20] C. C. Ventola, “The nanomedicine revolution: Part 1: Emerging concepts,” P&T, vol. 37, no. 9, pp. 512–525, 2012.